Oncomine®BRCA1/2 Panel accurately detects pathogenic BRCA1/2 variants in patients with breast and/or ovarian cancer, so is feasible for use in cancer genome research and diagnostic purposes in a clinical setting. Here, BRCA1 is linked to ovarian carcinoma.